https://www.crescendobiologics.com/hello-world/ 2024-03-07T09:08:01+00:00 https://www.crescendobiologics.com/new-biotechnology-publication-validates-crescendo-biologics-platform-as-it-moves-towards-the-clinic/ 2024-03-07T09:08:01+00:00 https://www.crescendobiologics.com/clinical-development/ 2024-03-07T09:08:01+00:00 https://www.crescendobiologics.com/crescendo-biologics-strengthens-leadership-team-with-appointment-of-ex-gsk-stewart-kay-as-chief-business-officer/ 2024-03-07T09:08:01+00:00 https://www.crescendobiologics.com/chief-medical-officer/ 2024-03-07T09:08:01+00:00 https://www.crescendobiologics.com/crescendo-biologics-and-cancer-research-uk-sign-clinical-development-partnership-to-develop-cb213-a-novel-bispecific-humabody-therapeutic-2/ 2024-03-07T09:08:01+00:00 https://www.crescendobiologics.com/crescendo-biologics-to-collaborate-with-world-leading-oncology-groups-at-the-university-of-oxford-and-the-university-of-surrey/ 2024-03-07T09:08:01+00:00 https://www.crescendobiologics.com/publication-in-cancer-research-demonstrates-crescendo-biologics-humabody-vh-therapeutics-outperform-conventional-antibodies-in-vivo/ 2024-03-07T09:08:01+00:00 https://www.crescendobiologics.com/crescendo-biologics-enters-pre-clinical-collaboration-with-orano-med-to-explore-targeted-alpha-therapy/ 2024-03-07T09:08:01+00:00 https://www.crescendobiologics.com/crescendo-biologics-reaches-fifth-milestone-in-its-strategic-collaboration-with-takeda/ 2024-03-07T09:08:01+00:00 https://www.crescendobiologics.com/crescendo-biologics-appoints-dr-kenji-hashimoto-as-chief-medical-officer/ 2024-03-07T09:08:01+00:00 https://www.crescendobiologics.com/crescendo-biologics-second-oncology-targeted-humabody-licensed-by-takeda/ 2024-03-07T09:08:01+00:00 https://www.crescendobiologics.com/crescendo-biologics-presenting-at-key-industry-events-during-october-2019/ 2024-03-07T09:08:01+00:00